We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

93 hedge funds and large institutions have $888M invested in Adaptimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

303% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $2.56M

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

34% more capital invested

Capital invested by funds: $663M → $888M (+$225M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

8% more funds holding

Funds holding: 86 → 93 (+7)

1.68% more ownership

Funds ownership: 9.88% → 11.57% (+1.7%)

50% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 36

Holders
93
Holders Change
+7
Holders Change %
+8.14%
% of All Funds
2.13%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
18
Increased
18
Reduced
36
Closed
11
Calls
$10.3M
Puts
$2.56M
Net Calls
+$7.74M
Net Calls Change
+$6.31M

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$65.8M
2
NMC
NEA Management Company
Maryland
+$26.2M
3
Millennium Management
Millennium Management
New York
+$13.9M
4
SLG
Stanley-Laman Group
Pennsylvania
+$5.93M
5
FCM
Frontier Capital Management
Massachusetts
+$5.7M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.4M
2
TCM
Tekla Capital Management
Massachusetts
-$5.28M
3
OIM
Oracle Investment Management
Connecticut
-$5.2M
4
Capital World Investors
Capital World Investors
California
-$4.13M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
76
Cutler Group
California
$71K +$7.34K +700 +15%
Wells Fargo
77
Wells Fargo
California
$38K -$14.7K -1,400 -33%
SPIA
78
Steward Partners Investment Advisory
New York
$27K – – –
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$14K – – –
KBC Group
80
KBC Group
Belgium
$13K – – –
SMFS
81
Squar Milner Financial Services
California
$9K – – –
RE
82
RBC Europe
United Kingdom
$8.14K – – –
TRCT
83
Tower Research Capital (TRC)
New York
$7K -$15.4K -1,465 -75%
Bank of America
84
Bank of America
North Carolina
$6K -$36.1K -3,439 -88%
NFG
85
Next Financial Group
Texas
$6K +$4.98K +475 New
MYIA
86
Mount Yale Investment Advisors
Colorado
$6K +$8.73K +833 New
CAG
87
Csenge Advisory Group
Florida
$5K +$10.5K +1,003 New
Daiwa Securities Group
88
Daiwa Securities Group
Japan
$4K – – –
ASN
89
Advisory Services Network
Georgia
$2K – – –
LTFS
90
Ladenburg Thalmann Financial Services
Florida
$2K +$1.42K +135 New
ED
91
Exane Derivatives
France
$1.61K -$139K -13,251 -99%
Barclays
92
Barclays
United Kingdom
$1K -$367K -35,053 -100%
RCAG
93
Rehmann Capital Advisory Group
Michigan
$650 – – –
Lazard Asset Management
94
Lazard Asset Management
New York
– -$1.91M -160,892 Closed
BBA
95
Baker Bros. Advisors
New York
– -$1.19M -100,000 Closed
Arrowstreet Capital
96
Arrowstreet Capital
Massachusetts
– -$815K -68,665 Closed
Squarepoint
97
Squarepoint
New York
– -$596K -50,200 Closed
PA
98
Perceptive Advisors
New York
– -$585K -49,302 Closed
FAM
99
Fred Alger Management
New York
– -$297K -25,000 Closed
TMC
100
Trellus Management Company
Florida
– -$195K -16,464 Closed
1 2 3
4
5

ADAP Hedge Fund Activity: Q3 2018 in Review

93 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2018, worth a combined $888M — up 34% from $663M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ADAP positions and 11 closed out — a net gain of 7 holders — while 18 added to existing stakes and 36 trimmed.

The largest buyer was Matrix Capital Management Company, adding an estimated $65.8M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.

  • 93 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2018, up from 86 in Q2 2018.
  • Funds reported $888M of Adaptimmune Therapeutics stock for Q3 2018, up 34% quarter-over-quarter.
  • 18 funds opened new Adaptimmune Therapeutics positions in Q3 2018 and 11 closed out, a net change of +7 holders.
  • The largest Adaptimmune Therapeutics buyer in Q3 2018 was Matrix Capital Management Company, an estimated $65.8M added.
  • The largest Adaptimmune Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2018.